GRI Bio Announces Reverse Stock Split
Why it matters
GRI Bio, a biotechnology company, announced a 1-for-28 reverse stock split, effective January 26, 2026, aiming to increase the company's stock price and potentially improve its market presence.
Article tone
Expected market reaction
Market impact analysis based on bullish sentiment with 80% confidence.
Evidence trail
Evidence
AI provenance
Technical identifiers
- Provider tag
- groq-llama-3.1-8b-instant
- Analysis version
- groq-llama-3.1-8b-instant
- Article id
- 35525
Original source
GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 26, 2026 LA JOLLA, CA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the board of directors of the Company approved a 1-for-28 reverse stock split (the “Reverse Split”) of the Company’s commo
Read the full article on Yahoo Finance
Original article published by Yahoo Finance on January 22, 2026. Analysis and insights provided by AnalystMarkets AI.